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ATP synthase is a key enzyme of mitochondrial energy conversion. In mammals, it produces most of cellular ATP. Alteration of ATP synthase
biogenesis may cause two types of isolated defects: qualitative when the enzyme is structurally modified and does not function properly, and
quantitative when it is present in insufficient amounts. In both cases the cellular energy provision is impaired, and diminished use of mitochondrial
ΔμH+ promotes ROS production by the mitochondrial respiratory chain. The primary genetic defects have so far been localized in mtDNA ATP6
gene and nuclear ATP12 gene, however, involvement of other nuclear genes is highly probable.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mitochondrial diseases; ATP synthase; Biogenesis; ATP6; ATP12; Energy provision; Reactive oxygen species1. Introduction
Inherited dysfunction of mitochondrial oxidative phosphor-
ylation system is increasingly recognized as a frequent cause of
human disease [1]. Most of the protein subunits of the mito-
chondrial respiratory chain are encoded by nuclear genes, while
only 13, but essential, subunits are encoded by mitochondrial
DNA (mtDNA). Mitochondrial energy provision thus uniquely
depends on two genomes. Numerous nuclear and mtDNA mu-
tations have been identified in affected patients to cause com-
bined defects as well as isolated disorders of individual oxidative
phosphorylation enzymes, including mitochondrial ATP
synthase. Most isolated defects of ATP synthase are associated
with alterations in the biosynthesis of the enzyme and can be
caused by mutations in subunit genes or in ancillary proteins
essential for the enzyme assembly. The ATP synthase is a key
component of mitochondrial energy conversion in the mamma-
lian organism as it produces most of the cellular ATP in aerobic
cells. No wonder that pronounced defects of this enzyme result
in mitochondrial diseases which are highly deleterious and man-
ifest primarily in children, very often shortly after birth.Abbreviations: ATP synthase, F1Fo-ATP synthase; F1— catalytic part of ATP
synthase, Fo — membrane sector part of ATP synthase; mtDNA, mitochondrial
DNA; ROS, reactive oxygen species; NARP, neuropathy, ataxia and retinitis
pigmentosa
⁎ Corresponding author. Tel.: +420 2 4106 2434; fax: +420 2 4106 2149.
E-mail address: houstek@biomed.cas.cz (J. Houštěk).
0005-2728/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbabio.2006.04.0062. ATP synthase biogenesis
Mitochondrial ATP synthase is composed of a catalytic F1
part connected by two stalks with a membrane-embedded Fo
part. The mammalian enzyme is built of at least 16 different
subunits (F1: α3β3γδε+IF1, Fo: a, b, c10, d, e, f, g, F6, A6L,
OSCP, (factor B)) [2–4] of which two Fo subunits — the
subunit a (subunit 6) and subunit A6L are encoded by mito-
chondrial DNA (mtDNA). ATP synthase complex is formed
stepwise with the assistance of several assembly factors but the
mechanism of how the mammalian ATP synthase assembles
from individual subunits is still not well understood. In the case
of F1, a close similarity of its structure in all types of energy-
transducing membranes suggests an analogous assembly
mechanism in mammalian cells, lower eukaryotes and prokar-
yotes. Concerning the Fo, the situation is complicated by in-
creasing evolutionary complexity of the Fo structure, which
gained 7 new subunits from bacteria to man. Most of the present
knowledge of mitochondrial ATP synthase biogenesis origi-
nates from studies in yeast but the assembly process in
mammalian cell might be modified as there are substantial
differences between higher and lower eukaryotes such as the
number and location of Fo subunit c genes, ATP synthase-
specific assembly factors, or factors regulating transcription of
mtDNA-encoded ATP synthase genes.
It has been shown that F1 assembles in mitochondria of a
yeast cytoplasmic petite mutant producing nonfunctional Fo [5]
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channel of the Fo portion has not been observed in mitochondria
lacking the β subunit [7]. Ordered assembly of the yeast Fo
sector was demonstrated using mutants for the mitochondrially
encoded subunits [8]. A principal role of subunit 9 (subunit c)
was suggested as in its absence subunits 6 and 8 (equivalent to
A6L) were not associated with the enzyme complex. Sequential
addition of mitochondrially-synthesized subunits was proposed
to start with subunit c, followed by subunit 8 and then subunit 6.
Moreover, subunit 6 was absent in cells devoid of any of the
stator-stalk subunits: subunit b [9], OSCP [10] and subunit d
[11], which might assemble in the order of b, OSCP and subunit
d [12].
Similarly, in human cells, the incorporation of subunit 6 ap-
pears to be at the late stage of enzyme assembly (Fig. 1), as
shown by the composition of assembly intermediates in cells
with doxycycline-arrested mitochondrial protein synthesis [13],
8993 mutation in ATP6 gene [14,15] or diminished content of
subunit 6 due to altered processing of the ATP6-COX3 transcript
[16]. Combination of pulse-chase labelling and two-dimensional
electrophoretic methods led to the following scheme: assembly
starts with the formation of F1, which then directs a sequential
assembly of the membranous part. After the attachment of F1 to
subunit c, subcomplexes are formed, involving other nuclear-
encoded subunits including subunits b, OSCP and F6. The in-
corporation of mitochondrially encoded subunits 6 and A6L
completes the formation of the ATP synthase [13].
ATP synthase assembly depends on the assistance of multiple
proteins that have substrate-specific chaperone-type functions.
Altogether 5 factors have been identified in yeast, of which
Atp11p and Atp12p mediate the formation of the F1 moiety via
interaction with subunits β and α, respectively (for review see
[17]). The role of Fmc1p in F1 assembly is less clear [18].
Atp10p and Atp22p are essential for the formation of the Fo part
during which Atp10p assists in the incorporation of the subunit 6
[19,20]. Inmammalian cells only the orthologues of yeastATP11
and ATP12 but no Fo-specific assembly factors have been foundFig. 1. Assembly of the mammalian ATP synthase. ATP synthase is formed in sever
specific ancillary factors, Atp11 and Atp12, not belonging to the final complex. In
formation of F1 (Fmc1p) and Fo (Atp10p, Atp22p).[21,22] (Fig. 1). Nevertheless, the existence of specific factors
involved in mammalian Fo formation is quite probable.
Further steps in the mammalian ATP synthase biogenesis
include generation of dimers with the aid of subunits e and g
[23], formation of higher oligomers (V1–V4) [24] and possibly
also supercomplexes with other inner mitochondrial membrane
proteins, e. g. with phosphate and adenine nucleotide carriers in
the “phosphorylating assembly” — so called ATP synthasome
[25,26]. Moreover, numerous recent studies identified ectopic
location of ATP synthase on the plasma membrane surface of
several types of mammalian cells. While the experimental evi-
dence for the functional involvement in intracellular signalling
as a receptor for apolipoprotein A-I [27], angiostatin [28], or
enterostatin and beta-casomorphin1-7 [29] of ectopic ATP
synthase in different cell types is quite convincing, nothing is
known about the mechanism by which the ATP synthase gets
there. It might possibly be transferred from mitochondria as a
complete enzyme by membrane fusion.
The cellular content of mammalian ATP synthase relative to
other respiratory chain enzymes is rather stable in many tissues,
and biogenesis of ATP synthase requires coordination of nuclear
and mitochondrial genomes and generally shares the common
regulatory cascades with other mitochondrial oxidative phos-
phorylation complexes [30,31]. Up- and down-regulation of
ATP synthase biogenesis involves both transcriptional and
posttranscriptional regulation [32]. The amount of ATP synthase
may be controlled by the availability of subunit c. This was
demonstrated in the thermogenic brown fat where the ATP
synthase content was physiologically reduced up to 10-fold due
to depressed transcription of subunit c gene [33]. It has been
further shown that c subunit overexpression can restore, at least
in part, the ATP synthase content in brown fat. The expression of
subunit c genes seems to determine the ATP synthase content in
other tissues as well [34,35]. Indeed, the existence of differently
organized [36] and regulated [34] isogenes coding for identical
subunit c would be advantageous for multiple factor regulation
of c subunit synthesis and thus ATP synthase biogenesis.al successive steps. Assembly of the F1-part is dependent upon the assistance of
the yeast enzyme, additional factors have been described to be involved in the
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Generalized decrease in the content of human ATP synthase
or alteration of its structure and function are associated with
severe pathological states resulting in typical mitochondrial
diseases. There are two types of isolated deficiency of ATP
synthase that have been described, differing in the pathogenic
mechanism, biochemical phenotype (structural and functional)
as well as in clinical presentation.
The first, and long well-known type, are qualitative defects of
ATP synthase caused by mutations in one of mtDNA-encoded
ATP synthase subunits — the protonophoric subunit 6 [37].
Maternally transmitted mutations in the ATP6 gene are
heteroplasmic and pathogenic phenotype correlates with their
mutation load [38]. Of the five missense mutations described so
far, the T8993G mutation that leads to the Leu156→Arg ex-
change is the most harmful (see [39]). At a high mutation load,
up to approximately 95%, it manifests as neuropathy, ataxia, and
retinitis pigmentosa (NARP) or as fatal encephalopathy known
as Leigh syndrome [40]. Subunit 6 operates together with the
ring of subunits c as the Fo proton channel and proton trans-
location from the intermembrane space to the matrix induces c
ring rotation that is transmitted to the F1 moiety, thus driving
ATP synthesis [41]. ATP6 missense mutations prevent ATP
synthesis but the reverse reaction, ATP hydrolysis, is possible.
On the basis of subunit a mutation in bacteria it has been
proposed that the H+ translocation is impaired [42] but later on it
was shown that NARP cells are capable of ATP-driven H+-
translocation [43] and that mutated Fo can translocate protons
from the cytosol to the matrix side of the inner mitochondrial
membrane [44]. Therefore, it appears that ATP6 mutations
disturb the intraenzyme coupling of H+-transport with the c-ring
rotation and ATP synthase is unable to utilize the proton trans-
location down the membrane proton gradient for the phosphor-
ylation of ADP.
A different form of qualitative ATP synthase deficiency is
represented by another type of ATP6mutation, microdeletion of
TA in position 9205–6 (ΔTA9205). This mutation is very rare,Fig. 2. Pathogenic mechanism of ATP synthase defects —only two cases having been found to date [16,45]. In mammalian
mtDNA the 5′-part of the ATP6 gene partly overlaps with the
ATP8 (A6L) gene and the 3′-end is followed by the COX3 gene.
A primary tricistronic transcript is cleaved and polyadenylated to
mature ATP8/ATP6 bicistronic mRNA and COX3 mRNA. The
hypothesis that the mutation removes the STOP codon of ATP6
and also the cleavage site between ATP6 and COX3 transcripts
[45] was confirmed in a patient with severe encephalopathy [16]
where a several-fold decrease of ATP6 and COX3 mRNAs was
found. It resulted in diminished synthesis and cellular content of
subunit 6, thus producing subunit 6-less enzyme capable of
hydrolyzing but not synthesizing ATP. Absence of subunit 6 also
interfered with the assembly mechanism leading to the accu-
mulation of incomplete assemblies [16], similar to those ob-
served in cells with T8993Gmutation or cells with doxycycline-
inhibited translation of mtDNA-encoded proteins. The primary
problem in ΔTA9205 mutation seems to be the tricistronic
ATP8/ATP6-COX3 transcript processing. Interestingly, this was
only little affected in the other homoplasmic case [46], which
also differed biochemically and clinically in normal biosynthesis
of subunit 6, unaltered mitochondrial ATP production [47] and
very mild presentation of transient hyperlactacidemia. This un-
explained difference in the manifestation of ATP6 homoplasmic
mutation indicates the existence of a factor, as yet unknown, that
is apparently involved in mitochondrial ATP6-COX3 mRNA
processing.
The second currently known type of isolated disorders of ATP
synthase are quantitative defects in which the cellular content of
the enzyme is selectively reduced to less than 30% of the control,
relative to the content of respiratory chain enzymes [48]. The
disorder is of nuclear genetic origin, patients do not show any
mutations in mtDNA ATP6 and ATP8 genes, and ATP synthase
content is fully restored by replacement of the nucleus in trans-
mitochondrial cybrids [49]. The biosynthesis of ATP synthase is
inhibited but the expression of genes coding for enzyme subunits
is not changed, including the level of transcripts of subunit c.
Unlike ATP6 mutations, the ATP synthase-deficient cells do not
show accumulation of any incomplete assemblies, and it has beenenergy deprivation and increased ROS production.
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sembly when the F1 is formed [49]. At present, more than dozen
patients with ATP synthase deficiency have been diagnosed [48–
53]. Most of them display a remarkably uniform phenotype with
an early onset already in newborns, severe and often fatal hyper-
lactacidemia, hypertrophic cardiomyopathy and elevated levels of
3-methylglutaconic acid in urine. About half of the patients die
within the first days ormonths of life; however, long survival even
for years, is also possible. Degenerative necrotic changes in the
brain stem, typical of ATP6 mutations, are rare. Detailed
investigation of F1 assembly factors showed in one case with
pronounced brain atrophy a homozygous TGG-AGG missense
mutation in exon 3 ofATP12 changing Trp94 toArg in the Atp12p
assembly factor [53]. However, in others, clinically distinct case
mutations in ATP11 and ATP12 were excluded, and normal
expression of the F1-assembly genes was found. Interestingly, this
contrasts with the situation of ATP synthase-poor brown adipose
tissue where ATP12 mRNA is highly upregulated [54]. Ap-
parently, the quantitative disorders of ATP synthase are caused by
different genetic defects that remain to be identified. They may
include additional mammalian ATP synthase-specific assembly
factors that have not yet been recognized.
4. Two components of the pathogenic mechanism in ATP
synthase disorders
Both types of ATP synthase disorders result in a decreased
ability of mitochondria to produce ATP in patient cells. This has
been clearly shown for ATP6 mutations as well as for quan-
titative defects of ATP synthase. In milder mutations of ATP6,
the ATP synthesis is clearly less affected than in the T8993G
patients [14,15,55–58]. Experiments with T8993G cybrids and
fibroblasts revealed an up to 5- to 20-fold decrease in ATP
production at or near to homoplasmic state. A similarly pro-
nounced decrease has been found in quantitative defects of ATP
synthase that display only 10–30% of normal enzyme content.
Substrate-supported mitochondrial ATP production in permea-
bilized cells was decreased to 30% or even more, depending on
the substrates [49,51]. Indeed, in both types of ATP synthase
disorders the ATP production measurements have been
performed in cells that are largely glycolytic, such as cultured
fibroblasts, cybrids or blood cells. The key question is how the
altered function of ATP synthase affects the ATP production in
patient tissues in vivo and how important it is for biochemical
and clinical phenotype of the disease. The mainly affected
tissues, brain and heart, primarily rely on oxidative metabolism
and it is expected that a decline of aerobic energy provision can
have deleterious effects on their function and morphology.
Studies in mice indicate that due to nonlinear dependence of
coupled respiration on ATP synthase content, significant ATP
synthesis is to be expected even when the ATP synthase activity
is very low. This is apparent from ATP synthase threshold values
in different tissues [59,60]. Similar data for human tissues are
missing, but even here, there must exist a significant spare
capacity of ATP synthase, otherwise the patients with ATP
synthase content reduced to 10% of the control would not be able
to survive at all.The low ability of mitochondria to utilize respiration-gene-
rated proton gradient for ATP synthesis generally means that the
mitochondrial membrane remains hyperpolarized, which may
lead to increased generation of reactive oxygen species (ROS) by
the respiratory chain [61]. It has been demonstrated that the cells
with ATP6 mutations maintain high values of ΔΨ [51,57] and
also the cells from patients with quantitative defects of ATP
synthase displayed increased ΔΨ in state 3 (ADP) as well as in
state 4 [49,62]. In both types of ATP synthase disorders, it was
also documented that high ΔΨ values indeed cause increased
ROS production. The T8993G mutation caused an increase in
MnSOD and in ROS levels determined with the fluorescent
probe DCFDA [57,63]. Similarly, cells with quantitative defects
ofATP synthase showed elevated levels of ROS and upregulation
of antioxidative defence components [48,62]. Importantly,
increased ROS production in both types of disorders was
prevented by the uncoupler FCCP, indicating that it was the high
membrane potential that upregulated the ROS production.
For a long time, uncompensated ROS production has been
implicated in the pathogenesis of human mitochondrial diseases
[64]. Now it appears that, besides complex I defects [65–67], the
increased oxidative stress represents an important factor of the
molecular pathogenic mechanism also in isolated disorders of
ATP synthase. Thus, energy deprivation and elevated ROS pro-
duction are the two major components of the pathogenic mech-
anism in isolated defects of ATP synthase that are closely related
to each other (Fig. 2). At present, it is difficult to say which one is
more important for the manifestation of the disease and whether a
different proportion between ROS production and decline in
mitochondrial ATP synthesis can be responsible for distinct
clinical phenotypes in qualitative and quantitative ATP synthase
disorders. Nevertheless, different types of antioxidants, such as
perfluoro-tris-phenylnitrone, N-acetylcysteine, dihydrolipoic
acid or Coenzyme Q10, had an apparent beneficial effect on the
level of ROS production, the cell viability, occurrence of apop-
totic markers and even ATP production in NARP cells with
T8893G mutation [57,63], which makes the ROS production a
promising target for the therapy in isolated disorders of ATP
synthase.
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